Importantly, we found that eIF4A3 was a cofactor for ALYREF in HCC, and so a comprehensive analysis of the regulatory events for both ALYREF and eIF4A3 may help to better understand HCC progression. Here, ALYREF is linked to hepatocellular carcinoma.